Currently, however, most of the described biomarkers have limited clinical applicability, although at the same time they have quite significant uses in efforts to identify pathways associated with HF onset and progression.
1
—
—
Currently, however, most of the described biomarkers have limited clinical applicability, although at the same time they have quite significant uses in efforts to identify pathways associated with HF onset and progression.